ATE364044T1 - 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit - Google Patents

5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit

Info

Publication number: ATE364044T1
Authority: AT; Austria
Prior art keywords: obesity; treatment; diabetes; receptor agonists; sup
Prior art date: 2003-06-26

Application number

AT04740057T

Other languages

English (en)

Inventor

Toby Jonathan Blench

Paul Hebeisen

Hans Richter

Stephan Roever

Original Assignee

Hoffmann La Roche

Vernalis Res Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-26

Filing date

2004-06-18

Publication date

2007-06-15

2004-06-18 Application filed by Hoffmann La Roche, Vernalis Res Ltd filed Critical Hoffmann La Roche

2007-06-15 Application granted granted Critical

2007-06-15 Publication of ATE364044T1 publication Critical patent/ATE364044T1/de

Links

208000008589 Obesity Diseases 0.000 title abstract 2
235000020824 obesity Nutrition 0.000 title abstract 2
102000006902 5-HT2C Serotonin Receptor Human genes 0.000 title 1
108010072553 5-HT2C Serotonin Receptor Proteins 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1
239000000018 receptor agonist Substances 0.000 title 1
229940044601 receptor agonist Drugs 0.000 title 1
150000002148 esters Chemical class 0.000 abstract 1
150000004885 piperazines Chemical class 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229940066771 systemic antihistamines piperazine derivative Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyridine Compounds (AREA)

AT04740057T 2003-06-26 2004-06-18 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit ATE364044T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0314967.1A GB0314967D0 (en)	2003-06-26	2003-06-26	Piperazine derivatives

Publications (1)

Publication Number	Publication Date
ATE364044T1 true ATE364044T1 (de)	2007-06-15

Family

ID=27637436

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04740057T ATE364044T1 (de)	2003-06-26	2004-06-18	5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit

Country Status (14)

Country	Link
US (1)	US7208494B2 (de)
EP (1)	EP1641796B1 (de)
JP (1)	JP4362511B2 (de)
KR (1)	KR100756113B1 (de)
CN (1)	CN100400538C (de)
AT (1)	ATE364044T1 (de)
AU (1)	AU2004251847B2 (de)
BR (1)	BRPI0411936A (de)
CA (1)	CA2530308C (de)
DE (1)	DE602004006869T2 (de)
ES (1)	ES2287741T3 (de)
GB (1)	GB0314967D0 (de)
MX (1)	MXPA05013856A (de)
WO (1)	WO2005000849A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5173190B2 (ja)	2004-08-25	2013-03-27	武田薬品工業株式会社	腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
CA2609634C (en) *	2005-05-03	2011-02-01	F. Hoffmann-La Roche Ag	Tetracyclic azapyrazinoindolines as 5-ht2 ligands
WO2006125179A1 (en) *	2005-05-19	2006-11-23	Xenon Pharmaceuticals Inc.	Tricyclic compounds and their uses as therapeutic agents
US20090203750A1 (en) *	2005-08-24	2009-08-13	Alan Kozikowski	5-HT2C Receptor Agonists as Anorectic Agents
US7622466B2 (en) *	2005-11-18	2009-11-24	Hoffman-La Roche Inc.	Azaindole-2-carboxamide derivatives
ES2333672T3 (es)	2005-12-09	2010-02-25	F. Hoffmann-La Roche Ag	Derivados de amida triciclica para tratamiento de obesidad.
JP5528699B2 (ja)	2006-05-16	2014-06-25	武田薬品工業株式会社	縮合複素環化合物およびその用途
EP2034916A1 (de) *	2006-07-04	2009-03-18	Bracco Imaging S.p.A	Vorrichtung zur lokalen wärmeablation von biologischem gewebe, insbesondere tumor- und ähnlichem gewebe
JP5520051B2 (ja)	2007-11-15	2014-06-11	武田薬品工業株式会社	縮合ピリジン誘導体およびその用途
US8410284B2 (en)	2008-10-22	2013-04-02	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011071136A1 (ja)	2009-12-11	2011-06-16	アステラス製薬株式会社	線維筋痛症治療剤
AU2011212930B2 (en)	2010-02-04	2016-02-11	The Board Of Trustees Of The University Of Illinois	Highly selective 5-HT(2C) receptor agonists having antagonist activity at the 5-HT(2B) receptor
JP2013520502A (ja)	2010-02-25	2013-06-06	メルク・シャープ・エンド・ドーム・コーポレイション	有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US20130267500A1 (en)	2010-09-01	2013-10-10	Arena Pharmaceuticals, Inc.	5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
CA2826649C (en)	2011-02-25	2016-07-26	Merck Sharp & Dohme Corp.	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20140045746A1 (en)	2012-08-02	2014-02-13	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2014139388A1 (en)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
WO2015066344A1 (en)	2013-11-01	2015-05-07	Arena Pharmaceuticals, Inc.	5-ht2c receptor agonists and compositions and methods of use
PL3250549T3 (pl)	2015-01-29	2021-12-13	The Board Of Trustees Of The University Of Illinois	Cyklopropylometanoaminy jako selektywni agoniści receptora 5-HT(2C)
WO2019131902A1 (ja)	2017-12-27	2019-07-04	武田薬品工業株式会社	腹圧性尿失禁および便失禁の治療薬
CN118574832B (zh) *	2022-01-19	2026-05-29	无锡奕拓医药科技有限责任公司	三并环化合物、其制备、药物组合物及应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3317524A (en) *	1965-02-04	1967-05-02	American Home Prod	Substituted 1, 2, 3, 4-tetrahydro-pyrazino[1, 2-a]indoles
CA1247547A (en) *	1983-06-22	1988-12-28	Paul Hadvary	Leucine derivatives
US4844839A (en) *	1984-09-04	1989-07-04	Manchak Frank	In situ treatment and analysis of wastes
US4776409A (en) *	1984-09-04	1988-10-11	Manchak Frank	Insitu waste impoundment treating apparatus and method of using same
CA1328881C (en)	1984-12-21	1994-04-26	Pierre Barbier	Process for the manufacture of oxetanones
CA1270837A (en) *	1984-12-21	1990-06-26	Hoffmann-La Roche Limited	Oxetanones
US5246960A (en) *	1984-12-21	1993-09-21	Hoffmann-La Roche Inc.	Oxetanones
EP0235249B1 (de) *	1985-08-26	1992-12-23	MANCHAK, Frank, Jr.	Vorrichtung zur in-situ-behandlung von gefährlichem abfall und deren verwendung
CA2035972C (en)	1990-02-23	2006-07-11	Martin Karpf	Process for the preparation of oxetanones
US5274143A (en)	1991-07-23	1993-12-28	Hoffmann-La Roche Inc.	Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
EP0572863A1 (de)	1992-06-05	1993-12-08	F. Hoffmann-La Roche Ag	ZNS Pyrazinoindole
HUT71799A (en) *	1993-03-01	1996-02-28	Merck Sharp & Dohme	Pyrrolo-pyridine derivatives, pharmaceutical compositions containing the same, process for producing them
TW334423B (en)	1993-10-22	1998-06-21	Hoffmann La Roche	Tricyclic 1-aminoethylpyrrole-derivatives
TW270114B (de)	1993-10-22	1996-02-11	Hoffmann La Roche
AU5343298A (en)	1997-01-13	1998-08-03	Yamanouchi Pharmaceutical Co., Ltd.	5-ht2c receptor agonists and aminoalkylindazole derivatives
US6004996A (en) *	1997-02-05	1999-12-21	Hoffman-La Roche Inc.	Tetrahydrolipstatin containing compositions
US6267952B1 (en)	1998-01-09	2001-07-31	Geltex Pharmaceuticals, Inc.	Lipase inhibiting polymers
PT1105123E (pt)	1998-08-14	2004-08-31	Hoffmann La Roche	Composicoes farmaceuticas contendo inibidores da lipase e quitosano
CA2340056C (en)	1998-08-14	2007-01-09	F. Hoffmann-La Roche Ag	Pharmaceutical compositions containing lipase inhibitors
GB9819033D0 (en) *	1998-09-01	1998-10-28	Cerebrus Ltd	Chemical compounds VI
GB9819035D0 (en) *	1998-09-01	1998-10-28	Cerebrus Res Ltd	Chemical compounds VII
GB9819020D0 (en)	1998-09-01	1998-10-28	Cerebrus Ltd	Chemical compounds III
GB9819019D0 (en)	1998-09-01	1998-10-28	Cerebrus Ltd	Chemical compounds II
GB9819032D0 (en) *	1998-09-01	1998-10-28	Cerebrus Ltd	Chemical compounds IV
GB9820767D0 (en)	1998-09-23	1998-11-18	Cerebrus Ltd	Chemical compounds VIII
HUP0104773A3 (en)	1998-12-17	2004-10-28	Wyeth Corp	2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one derivates being 5ht2c agonists, process for their preparation and medicaments containing them
GB9902047D0 (en) *	1999-01-29	1999-03-17	Cerebrus Ltd	Chemical compounds XI
GB9918965D0 (en)	1999-08-11	1999-10-13	Cerebrus Ltd	Chemical compounds xxi
GB9918962D0 (en) *	1999-08-11	1999-10-13	Cerebrus Ltd	Chemical compounds xxii
EP1132389A1 (de)	2000-03-06	2001-09-12	Vernalis Research Limited	Neue Azaindolyl-Derivate für die Behandlung von Fettleibigheit
US6635598B2 (en) *	2000-04-20	2003-10-21	Indian Petrochemicals Corporation Limited	Stable and selective dehydrogenation catalyst and a process for the preparation thereof
WO2002010169A1 (en) *	2000-07-31	2002-02-07	F. Hoffmann-La Roche Ag	Piperazine derivatives
BR0116605A (pt) *	2000-12-27	2003-09-30	Hoffmann La Roche	Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono
GB0202015D0 (en) *	2002-01-29	2002-03-13	Hoffmann La Roche	Piperazine Derivatives

2003
- 2003-06-26 GB GBGB0314967.1A patent/GB0314967D0/en not_active Ceased
2004
- 2004-06-18 CA CA002530308A patent/CA2530308C/en not_active Expired - Fee Related
- 2004-06-18 ES ES04740057T patent/ES2287741T3/es not_active Expired - Lifetime
- 2004-06-18 AU AU2004251847A patent/AU2004251847B2/en not_active Ceased
- 2004-06-18 BR BRPI0411936-3A patent/BRPI0411936A/pt not_active IP Right Cessation
- 2004-06-18 DE DE602004006869T patent/DE602004006869T2/de not_active Expired - Lifetime
- 2004-06-18 AT AT04740057T patent/ATE364044T1/de not_active IP Right Cessation
- 2004-06-18 WO PCT/EP2004/006612 patent/WO2005000849A1/en not_active Ceased
- 2004-06-18 KR KR1020057024843A patent/KR100756113B1/ko not_active Expired - Fee Related
- 2004-06-18 EP EP04740057A patent/EP1641796B1/de not_active Expired - Lifetime
- 2004-06-18 CN CNB2004800179181A patent/CN100400538C/zh not_active Expired - Fee Related
- 2004-06-18 MX MXPA05013856A patent/MXPA05013856A/es unknown
- 2004-06-18 JP JP2006515997A patent/JP4362511B2/ja not_active Expired - Fee Related
- 2004-06-25 US US10/876,954 patent/US7208494B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20050026925A1 (en)	2005-02-03
GB0314967D0 (en)	2003-07-30
EP1641796A1 (de)	2006-04-05
CA2530308C (en)	2009-06-09
ES2287741T3 (es)	2007-12-16
JP2007506667A (ja)	2007-03-22
WO2005000849A1 (en)	2005-01-06
CN100400538C (zh)	2008-07-09
BRPI0411936A (pt)	2006-08-29
AU2004251847B2 (en)	2007-08-23
US7208494B2 (en)	2007-04-24
KR100756113B1 (ko)	2007-09-05
KR20060028773A (ko)	2006-04-03
CN1812989A (zh)	2006-08-02
EP1641796B1 (de)	2007-06-06
MXPA05013856A (es)	2006-02-28
DE602004006869D1 (de)	2007-07-19
CA2530308A1 (en)	2005-01-06
AU2004251847A1 (en)	2005-01-06
DE602004006869T2 (de)	2008-02-07
JP4362511B2 (ja)	2009-11-11

Legal Events

Date

Code

Title

Description

2007-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1641796

Country of ref document: EP

2012-03-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE602004006869D1 (de)	2007-07-19	5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit
ATE327977T1 (de)	2006-06-15	Tetrahydrochinolin-derivate als crth2 antagonisten
BR0311541A (pt)	2006-06-06	indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas
TNSN04136A1 (en)	2007-03-12	Aza-arylpiperazines
ATE384058T1 (de)	2008-02-15	Thiazolderivate
EA200700118A1 (ru)	2007-08-31	Амидосоединения и их применение в качестве лекарственных средств
DE602004012858D1 (de)	2008-05-15	2-aminobenzothiazole als cb1 rezeptor inverse agonisten
SE0403006D0 (sv)	2004-12-09	New compounds
MY136761A (en)	2008-11-28	Oxazol derivatives
UY26291A1 (es)	2001-03-16	Compuestos químicos xxii
NO20090328L (no)	2009-01-26	Nye forbindelser 385
MX2007008614A (es)	2007-09-11	Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
NO20050851L (no)	2005-03-29	Kaspase-inhibitorer og anvendelser derav
SE0402762D0 (sv)	2004-11-11	Indazole sulphonamide derivatives
EA200601802A1 (ru)	2007-02-27	Производные морфолина
SE0201544D0 (sv)	2002-05-17	Novel compounds and thier use
TW200508207A (en)	2005-03-01	New benzimidazole derivatives
IS8485A (is)	2006-05-26	Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
ATE386725T1 (de)	2008-03-15	Heterocyclylverbindungen
SE0403171D0 (sv)	2004-12-23	New compounds
ATE507212T1 (de)	2011-05-15	Morpholine als 5ht2c-agonisten
MY143568A (en)	2011-05-31	11b-hsd1 inhibitors for the treatment of diabetes
SE0301699D0 (sv)	2003-06-10	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE369348T1 (de)	2007-08-15	Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
SE0401763D0 (sv)	2004-07-05	Compounds